Investment Rating - The report assigns an "Accumulate" rating to Fosun International, with a target price of HKD 7.24 per share, based on a NAV valuation of HKD 18.1 per share [8]. Core Insights - The valuation is currently low, with a clear strategic focus on core sectors, continuous improvement in asset quality, and a steady increase in credit ratings. The company's operational fundamentals are improving, with expected earnings growth and upward performance potential [2]. Financial Summary - Total revenue projections (in million RMB) for 2024A to 2028E are as follows: - 2024A: 192,142 (-3.06%) - 2025E: 170,932 (-11.04%) - 2026E: 180,434 (+5.56%) - 2027E: 191,091 (+5.91%) - 2028E: 203,521 (+6.50%) [4] - Net profit projections show a significant turnaround from a loss of 4.35 billion in 2024A to a profit of 4.13 billion in 2028E, indicating a recovery trajectory [4]. Company Overview - Fosun International is positioned as a global family consumption industry group, focusing on health, happiness, wealth, and intelligent manufacturing sectors. The company aims to enhance family life through a comprehensive service offering [12][21]. - The company has undergone a strategic "slimming down" process, divesting non-core assets and focusing on its main business areas, which has led to improved asset quality and financial leverage [8][26]. Strategic Focus - The company is concentrating on four main sectors: health, happiness, wealth, and intelligent manufacturing. Each sector is designed to provide comprehensive services and products to global families [21][22]. - The health sector is focused on pharmaceuticals, diagnostics, and health services, while the happiness sector emphasizes leisure, cultural consumption, and fashion brands. The wealth sector is centered on insurance and asset management, and the intelligent manufacturing sector targets strategic resources and new materials [21][22]. Performance Outlook - The company is expected to experience a rebound in profitability, with improved operational quality driving valuation increases. The credit rating has been upgraded, and cost reductions are anticipated to enhance profit margins [4][8]. - The health sector's revenue is projected to remain stable, with significant contributions from innovative drug developments and medical services, while the happiness sector faces challenges due to market conditions [35][41].

Market Performance - The Hong Kong stock market opened higher on February 25, with the Hang Seng Index rising by 0.58% to 26,745.2 points, the Hang Seng Tech Index up by 0.86% to 5,316.09 points, and the National Enterprises Index increasing by 0.68% to 9,069.19 points [1] - Major tech stocks saw gains, including Alibaba up 1.22%, Tencent Holdings up 0.48%, JD Group up 1.03%, NetEase up 1.51%, Meituan up 1.23%, and Kuaishou up 0.38% [1] - The AI application sector showed strong performance, with KEEP rising by 3.94%, Out of Home asking up 3.17%, Paradigm Intelligence up 2.82%, and Haizhi Technology Group up 2.38% [1] Company Earnings - Maoyan Entertainment (01896.HK) expects revenue for FY2025 to reach HKD 4.6 billion to 4.7 billion, a year-on-year increase of approximately 12.7% to 15.1%, with net profit projected at HKD 540 million to 590 million, a significant increase of about 196.9% to 224.4% [2] - Green Tea Group (06831.HK) anticipates a net profit of HKD 460 million to 508 million for 2025, representing a year-on-year increase of approximately 31.4% to 45.1% [2] - Fengsheng Life Services (00331.HK) reported a mid-term revenue of HKD 3.777 billion for the six months ending December 31, 2025, a decrease of 7.7% year-on-year, with net profit down 10.6% to HKD 216 million [2] - Baosheng Group (03368.HK) expects total operating revenue of RMB 3.698 billion for 2025, a decline of 0.8%, with same-store sales down 16.6%, and a loss of RMB 186 million, an increase of 6.35% year-on-year [2] - China Overseas Land & Investment (00127) anticipates a potential loss reduction of 75% to 85% for 2025, but expects revenue to decrease by 5% to 15% [2] - Digital Telecom (00315.HK) reported mid-term revenue of HKD 3.561 billion, a year-on-year increase of 2%, with profit rising by 8% to HKD 278 million [2] Strategic Collaborations - Haizhi Technology Group (02706.HK) has entered into a strategic cooperation framework agreement with Zhiyu (02513.HK) to collaborate in model training and application scenarios [3] Share Buybacks and Holdings - Conch Cement (00914.HK) plans to increase its holdings in the company’s A-shares by HKD 700 million to 1.4 billion, reflecting confidence in future development [8] - Xiaomi Group (01810.HK) repurchased 2.7942 million shares for HKD 99.998 million at prices ranging from HKD 35.64 to 35.92 [8] - Geely Automobile (00175.HK) repurchased 3.18 million shares for HKD 53.2801 million at prices between HKD 16.67 and 17.1 [8] - NetEase Cloud Music (09899.HK) repurchased 93,700 shares for HKD 14.9998 million at an average price of HKD 160.08 [8] - Meitu (01357.HK) repurchased 219,850 shares for HKD 12.5009 million at prices ranging from HKD 5.64 to 5.73 [8] Institutional Insights - Galaxy Securities believes the technology sector remains a long-term investment focus, with potential for rebound due to reduced valuation pressure and accelerated AI application advancements [9] - Longcheng Securities reports that global grid investment has rapidly increased since 2020, with expectations for 2024 to reach USD 390 billion and over USD 400 billion in 2025, indicating a strong demand for electrical equipment in the U.S. [9]

Group 1 - AMD and Meta have reached a strategic partnership agreement for the procurement of AI chips worth up to $60 billion over the next five years, marking a significant shift in the AI chip market dynamics [1] - This agreement signifies Meta's transition from being a hardware buyer to a strategic partner in the supply chain, providing AMD with its largest single order in history [1] - AMD's AI chips, such as the MI300 series, rely heavily on advanced packaging technologies like CoWoS, indicating a substantial demand for high-quality packaging capabilities [1] Group 2 - ASMPT, a leading semiconductor packaging equipment supplier, is expected to benefit directly from the expansion of AMD and the overall industry due to its key equipment for advanced packaging [2] - The major demand for advanced packaging capacity is driven by Meta's large order, with TSMC being the primary provider of CoWoS capacity [1][2] Group 3 - The Nasdaq China Golden Dragon Index rose by 1.37%, reflecting a positive trend in popular Chinese concept stocks, including AMD, which saw an increase of over 8% [3] - Major technology stocks, including Intel and Tesla, also experienced gains, contributing to the overall positive market sentiment [3] Group 4 - Panasonic has decided to transfer its TV sales business in North America and Europe to Skyworth, focusing instead on the Japanese market and high-end model production to reduce costs [4] - This strategic adjustment aligns with Panasonic's goal to optimize its operational model based on regional market conditions [4] Group 5 - Federal Pharmaceutical's UBT251 injection has completed Phase II clinical research in overweight/obese patients in China, indicating progress in its innovative drug development [5] - Haizhi Technology Group has entered a strategic cooperation framework agreement with Zhizhu Technology to collaborate in model training and application scenarios [6][7] Group 6 - Sanofi's partnership with Pfizer has led to significant revenue recognition, with a reported net profit of 2.939 billion yuan for 2025, reflecting a 317.09% year-on-year increase [8] - The company achieved a revenue of 4.199 billion yuan for the same period, marking a 251.81% increase [8] Group 7 - Harbin Electric has forecasted a net profit of 2.65 billion yuan for 2025, representing a year-on-year growth of approximately 57.2%, driven by increased revenue and improved product profitability [13] - The company is expected to benefit from the high demand for reliable power systems in the U.S. due to ongoing electricity shortages [13]

Group 1 - The company, Fuhong Hanlin (02696), announced a revised and partially terminated agreement with KGBio to terminate exclusive licensing rights for products in regions outside of Indonesia [1] - The company has also amended its licensing agreement with Abbott to expand the licensing area and milestone payment terms for licensed products, including the regions previously terminated with KGBio [1] - The termination of the commercial collaboration with KGBio allows the company to grant exclusive commercialization rights for the licensed products in the newly added regions to Abbott, enhancing the company's international market reach and product recognition [1]

Company News - Q Technology (01478.HK) reported a total sales volume of camera modules of 44.071 million units in January, representing a year-on-year increase of 22.8%. Fingerprint recognition module sales reached 19.741 million units, up 18.4% year-on-year, driven by increased overseas customer demand and a growing market share in the IoT and smart automotive sectors [2] - China Resources Power (00836.HK) achieved a sales volume of 23.78879 million megawatt-hours in January, a year-on-year increase of 28.4%. The sales from wind power plants increased by 7.2%, while solar power plant sales surged by 72.3% year-on-year [2] - NetEase-S (09999.HK) projected net revenue of approximately 112.626 billion yuan for 2025, a year-on-year growth of 6.96%, with net profit expected to be around 33.76 billion yuan, up 13.68% [2] - NetEase Cloud Music (09899.HK) anticipates revenue of about 7.759 billion yuan in 2025, with an expected profit of approximately 2.746 billion yuan, reflecting a significant year-on-year growth of 75.4%. The gross margin is expected to reach 35.7%, an increase from 33.7% in 2024, attributed to business scale growth, enhanced monetization capabilities, prudent cost management, and operational leverage [2] - Huitian Group (00806.HK) expects to achieve a consolidated profit attributable to shareholders of approximately 660 million HKD for the fiscal year 2025, a substantial increase from 31 million HKD in the previous year [2] Biotech Developments - Reborn Bio-B (06938.HK) entered into an exclusive global licensing agreement with Madrigal for several siRNA assets, receiving an upfront payment of 60 million USD, with potential cumulative payments of up to 4.4 billion USD upon achieving certain development, regulatory, and commercialization milestones, in addition to potential royalties on net sales [3] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase 1b/2 clinical study of HLX43 in combination with HLX07 or Hansizhuang® for patients with advanced or metastatic colorectal cancer in China [3] - Heng Rui Medicine (01276.HK) announced that its injection of Rukang Trastuzumab has been included in the list of breakthrough therapies, with global sales of similar products expected to reach approximately 6.557 billion USD in 2024 [3] - Saint Bella (02508.HK) made significant progress in its global strategic expansion plan, aiming to extend its reach to the eastern United States, the UK, France, Thailand, and Australia [3] - China National Biotech Group (08247.HK) signed a strategic cooperation agreement with Xiaoshou Medical to jointly promote the enhancement of quality medical resources and grassroots medical service capabilities [3] Buyback Activities - Geely Automobile (00175.HK) repurchased 1.201 million shares at a cost of 20.3042 million HKD, with repurchase prices ranging from 16.67 to 17.08 HKD [4] - Bairong Cloud-W (06608.HK) repurchased 1.66 million shares for 18.9051 million HKD, with share prices between 11.11 and 11.43 HKD [5] - Kingsoft (03888.HK) repurchased 355,200 shares at a cost of 9.9963 million HKD, with repurchase prices ranging from 27.9 HKD to 28.2 HKD [5]

Core Viewpoint - The company, Junshi Biosciences, has announced the completion of the first patient dosing in a 1b/2 clinical study of HLX43 in combination with HLX07 or Hansizhuang for patients with advanced or metastatic colorectal cancer in mainland China [1][2] Group 1 - The study aims to evaluate the safety, tolerability, and efficacy of HLX43 combined with HLX07 or Hansizhuang in patients with advanced or metastatic colorectal cancer [2] - The study consists of two parts: the first part includes a safety lead-in phase and a dose expansion phase, utilizing a 3+3 dose escalation design [2] - The primary objective of the first phase is to assess the safety and tolerability of different dose levels of HLX43 combined with HLX07, while secondary objectives include pharmacokinetics, immunogenicity, efficacy, and potential biomarkers [2] Group 2 - The second phase is a randomized, multi-center, open-label study evaluating HLX43 at two dose levels combined with fixed-dose HLX07, focusing on efficacy in metastatic colorectal cancer patients [2] - The secondary objectives of the second phase include evaluating safety and tolerability, pharmacokinetics, immunogenicity, and potential predictive or resistance biomarkers [2] - Additionally, the second part assesses HLX43 combined with fixed-dose Hansizhuang in metastatic colorectal cancer patients, with similar objectives regarding efficacy and safety [2]

Core Viewpoint - The announcement from Junshi Biosciences (复宏汉霖) indicates the initiation of a clinical study for HLX43 in combination with HLX07 or Hansizhuang (汉斯状®) for patients with advanced or metastatic colorectal cancer in mainland China [1] Group 1 - Junshi Biosciences has completed the first patient dosing in a 1b/2 phase clinical study for HLX43, a PD-L1 targeted antibody-drug conjugate [1] - The study involves the combination of HLX43 with HLX07, a recombinant humanized monoclonal antibody injection targeting EGFR, or Hansizhuang, a monoclonal antibody injection [1] - The clinical research is being conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1]

Major Events - Genting New Year (01952) subsidiary signed an agreement with Macao to commercialize MT1013 in Greater China and other Asian markets [1] - Junshi Biosciences (02696) entered into a licensing agreement with Eisai for Hansizhuang® to treat tumor indications [1] - Meituan-W (03690) plans to acquire all issued shares of Dingdong Fresh Holding Limited [1] - China Power (02380) subsidiary Xinyuan Zhichu signed a procurement contract for BESS with Tori [1] - Aimee Vaccine (06660) successfully passed the registration site inspection for its globally self-researched serum-free rabies vaccine [1] Operating Performance - NIO-SW (09866) issued a profit warning, expecting adjusted operating profit of 700 million to 1.2 billion yuan in Q4 2025, turning from loss to profit year-on-year [1] - Saint Bella (02508) issued a profit warning, expecting adjusted net profit of no less than 120 million yuan for 2025, a year-on-year increase of no less than 183% [1] - Geek+ (02590) achieved orders of 4.137 billion yuan in 2025, a year-on-year growth of approximately 31.7% [1] - China Overseas Development (00688) achieved contract property sales of approximately 14.478 billion yuan in January, a year-on-year increase of 20.4% [1] - Swire Properties (01972) reported a rental rate of 96% for Swire Plaza in Q4, with rents down by 13% [1] - Greentown China (03900) reported total contract sales of approximately 9.7 billion yuan in January, a year-on-year decrease of 14.16% [1]

Group 1 - The company Fuhong Hanlin (02696) has received approval from the National Medical Products Administration (NMPA) for a clinical trial application involving HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hanshuan® for the treatment of advanced solid tumors [1] - HLX43's phase 1 clinical data is set to be presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting and the 2025 World Lung Cancer Conference (WCLC), showing promising safety and preliminary efficacy in non-small cell lung cancer (NSCLC) and other solid tumors [2] - HLX07, an innovative biopharmaceutical developed by the company targeting the EGFR pathway, has demonstrated good safety and tolerability in a phase 1b/2 clinical study for advanced solid tumors [2] - Hanshuan® (sruvalizumab) has been approved for multiple indications in mainland China, including first-line treatment for squamous NSCLC, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous NSCLC [2] - The New Drug Application (NDA) for Hanshuan® in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer has been accepted by the NMPA and is included in the priority review process [2]

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received approval from the National Medical Products Administration (NMPA) for a clinical trial application involving HLX43, a PD-L1 targeted antibody-drug conjugate, in combination with HLX07 and Hansizhuang for the treatment of advanced solid tumors [1] Group 1 - The clinical trial will be conducted in China once conditions are met [1]